(DNLI) Denali Therapeutics - Ratings and Ratios
RIPK1 Inhibitor, eIF2B Activator, LRRK2 Inhibitor, ETV Therapy, OTV Therapy
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 61.9% |
| Value at Risk 5%th | 92.6% |
| Relative Tail Risk | -9.05% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.07 |
| Alpha | -38.30 |
| CAGR/Max DD | -0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.464 |
| Beta | 1.281 |
| Beta Downside | 1.155 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.20% |
| Mean DD | 36.27% |
| Median DD | 37.11% |
Description: DNLI Denali Therapeutics January 14, 2026
Denali Therapeutics (NASDAQ: DNLI) is a U.S. biotech focused on discovering and developing disease-modifying therapies for neurodegenerative and lysosomal storage disorders, leveraging its proprietary enzyme transport vehicle (TV) and omnipotent delivery (OTV) platforms.
The pipeline spans multiple modalities: a RIPK1 inhibitor (Eclitasertib) for peripheral inflammation; an eIF2B activator (DNL343) for ALS; LRRK2 inhibitor (BIIB122/DNL151) for Parkinson’s; frontotemporal dementia-granulin therapy (TAK-594/DNL593); enzyme-replacement candidates for Sanfilippo A (DNL126) and Hunter syndrome (DNL310); TV-based programs for Pompe disease (DNL952), Gaucher/Parkinson’s (DNL111), and Hurler syndrome (DNL622); and OTV/antibody TV candidates targeting tau, α-synuclein, and Aβ in Alzheimer’s and Parkinson’s disease.
As of the latest 10-Q (Q3 2024), Denali reported ~ $320 million in cash and equivalents, a burn rate of roughly $150 million per year, and a market-cap of ~ $2.1 billion-metrics that suggest a runway of just over two years without additional financing. The company’s valuation is heavily influenced by the broader biotech sector’s 2023-24 surge in CNS-focused R&D funding (CAGR ≈ 12 %) and by its strategic partnership with Biogen on the LRRK2 program, which could de-risk later-stage development. For a deeper, data-driven view of DNLI’s risk-adjusted upside, you may find it useful to explore the analyst tools on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.39 (>2.0%) and ΔFCFTA -13.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.38 (>3.0%) and CFO -397.8m > Net Income -498.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 9.79 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (172.4m) change vs 12m ago 1.75% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 22.73%; Δ -22.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.15 (EBITDA TTM -534.2m / Interest Expense TTM -49.1m) >= 6 (WARN >= 3) |
Altman Z'' -19.53
| (A) 0.75 = (Total Current Assets 882.6m - Total Current Liabilities 90.1m) / Total Assets 1.06b |
| (B) -1.82 = Retained Earnings (Balance) -1.92b / Total Assets 1.06b |
| warn (B) unusual magnitude: -1.82 — check mapping/units |
| (C) -0.44 = EBIT TTM -547.8m / Avg Total Assets 1.25b |
| (D) -14.84 = Book Value of Equity -1.92b / Total Liabilities 129.4m |
| Total Rating: -19.53 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.58
| 1. Piotroski 0.0pt |
| 2. FCF Yield -20.49% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda 0.09 |
| 6. ROIC - WACC (= -51.26)% |
| 7. RoE -46.33% |
| 8. Rev. Trend -57.19% |
| 9. EPS Trend -2.55% |
What is the price of DNLI shares?
Over the past week, the price has changed by +0.22%, over one month by +7.27%, over three months by +4.29% and over the past year by -21.92%.
Is DNLI a buy, sell or hold?
- Strong Buy: 15
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the DNLI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 32.9 | 82.7% |
| Analysts Target Price | 32.9 | 82.7% |
| ValueRay Target Price | 15.9 | -11.5% |
DNLI Fundamental Data Overview January 19, 2026
P/B = 3.0331
Revenue TTM = 0.0 USD
EBIT TTM = -547.8m USD
EBITDA TTM = -534.2m USD
Long Term Debt = 44.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 9.16m USD (from shortTermDebt, last quarter)
Debt = 44.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -46.6m USD (from netDebt column, last quarter)
Enterprise Value = 2.01b USD (2.81b + Debt 44.4m - CCE 848.2m)
Interest Coverage Ratio = -11.15 (Ebit TTM -547.8m / Interest Expense TTM -49.1m)
EV/FCF = -4.88x (Enterprise Value 2.01b / FCF TTM -410.8m)
FCF Yield = -20.49% (FCF TTM -410.8m / Enterprise Value 2.01b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 105.0m) / Revenue TTM)
Tobins Q-Ratio = 1.90 (Enterprise Value 2.01b / Total Assets 1.06b)
Interest Expense / Debt = 47.48% (Interest Expense 21.1m / Debt 44.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -432.8m (EBIT -547.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.79 (Total Current Assets 882.6m / Total Current Liabilities 90.1m)
Debt / Equity = 0.05 (Debt 44.4m / totalStockholderEquity, last quarter 926.2m)
Debt / EBITDA = 0.09 (negative EBITDA) (Net Debt -46.6m / EBITDA -534.2m)
Debt / FCF = 0.11 (negative FCF - burning cash) (Net Debt -46.6m / FCF TTM -410.8m)
Total Stockholder Equity = 1.08b (last 4 quarters mean from totalStockholderEquity)
RoA = -39.75% (Net Income -498.7m / Total Assets 1.06b)
RoE = -46.33% (Net Income TTM -498.7m / Total Stockholder Equity 1.08b)
RoCE = -48.88% (EBIT -547.8m / Capital Employed (Equity 1.08b + L.T.Debt 44.4m))
RoIC = -40.21% (negative operating profit) (NOPAT -432.8m / Invested Capital 1.08b)
WACC = 11.06% (E(2.81b)/V(2.85b) * Re(10.64%) + D(44.4m)/V(2.85b) * Rd(47.48%) * (1-Tc(0.21)))
Discount Rate = 10.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.68%
Fair Price DCF = unknown (Cash Flow -410.8m)
EPS Correlation: -2.55 | EPS CAGR: 25.09% | SUE: 4.0 | # QB: 1
Revenue Correlation: -57.19 | Revenue CAGR: -1.07% | SUE: -0.17 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.77 | Chg30d=+0.004 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-2.96 | Chg30d=+0.009 | Revisions Net=-3 | Growth EPS=+1.7% | Growth Revenue=+2279.9%
Additional Sources for DNLI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle